Risk factors for septic adverse events and their impact on survival in advanced ovarian cancer patients treated with neoadjuvant chemotherapy and interval debulking surgery

被引:3
作者
Son, Joo-Hyuk [1 ,2 ]
Lee, Joo-Hyung [2 ]
Jung, Jung-Ah [2 ]
Kong, Tae-Wook [1 ,2 ]
Paek, Jiheum [1 ,2 ]
Chang, Suk-Joon [1 ,2 ]
Ryu, Hee-Sug [1 ,2 ]
机构
[1] Ajou Univ, Sch Med, Div Gynecol Oncol, Suwon, South Korea
[2] Ajou Univ, Sch Med, Dept Obstet & Gynecol, Suwon, South Korea
关键词
Advanced ovarian cancer; Neutropenic sepsis; Septic adverse event; Overall survival; COMPLETE CYTOREDUCTION; AMERICAN SOCIETY; PACLITAXEL; ANEMIA; NEUTROPENIA; MANAGEMENT; ONCOLOGY; ADULTS; TIME;
D O I
10.1016/j.ygyno.2018.08.009
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Objectives. The aim of this study was to analyze risk factors for septic complications during adjuvant chemotherapy and their impact on survival in patients with advanced epithelial ovarian cancer treated with neoadjuvant chemotherapy (NAG) followed by interval debulking surgery (IDS). Methods. We retrospectively reviewed the medical records of 69 patients with advanced epithelial ovarian cancer from 2004 to 2017. All patients underwent three cycles of NAG followed by IDS and adjuvant chemotherapy. We identified grade 3 or 4 hematologic complications and severe adverse events accompanied by neutropenia, including sepsis or septic shock, that occurred during treatment. Clinicopathologic data including demographic factors, preoperative medical conditions, surgical procedures, and survival times were evaluated. Results. Of 69 patients, 27 (39.1%), 6 (8.8%), and 2 (2.9%) patients experienced grade 3 or 4 neutropenia, anemia, and thrombocytopenia, respectively, during NACT. Thirteen patients (18.8%) had a neutropenic fever with sepsis and 2 patients (2.9%) died of septic shock during adjuvant chemotherapy. Concurrent medical disease, splenectomy during IDS, and anemia or thrombocytopenia during NAG were significant risk factors for septic adverse events. In multivariate analysis, anemia (hemoglobin < 8 g/dL, p = 0.004) during NAG was the only significant factor associated with septic adverse events during adjuvant chemotherapy. Although there was no significant difference in progression-free survival, overall survival was significantly shorter in patients with septic adverse events (median, 82.3 vs. 17.3 months, p = 0.007). Conclusions. Grade 3 anemia during NAG may be an early indicator for septic adverse events during adjuvant chemotherapy. Considering the adverse impact on survival, scheme and dose of adjuvant chemotherapy should be tailored, and careful follow-up evaluation should be ensured in this patient group. (C) 2018 Elsevier Inc. All rights reserved.
引用
收藏
页码:32 / 38
页数:7
相关论文
共 50 条
  • [41] Primary Debulking Surgery Versus Neoadjuvant Chemotherapy in Advanced Epithelial Ovarian Cancer: A Propensity-matched Analysis
    Siesto, Gabriele
    Cavina, Raffaele
    Romano, Fabrizio
    Vitobello, Domenico
    AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2018, 41 (03): : 280 - 285
  • [42] Cost effectiveness of neoadjuvant chemotherapy followed by interval cytoreductive surgery versus primary cytoreductive surgery for patients with advanced stage ovarian cancer during the initial treatment phase
    Tran, Arthur-Quan
    Erim, Daniel O.
    Sullivan, Stephanie A.
    Cole, Ashley L.
    Barber, Emma L.
    Kim, Kenneth H.
    Gehrig, Paola A.
    Wheeler, Stephanie B.
    GYNECOLOGIC ONCOLOGY, 2018, 148 (02) : 329 - 335
  • [43] Interval debulking surgery for advanced epithelial ovarian cancer: A Cochrane systematic review
    Tangjitgamol, Siriwan
    Manusirivithaya, Sumonmal
    Laopaiboon, Malinee
    Lumbiganon, Pisake
    GYNECOLOGIC ONCOLOGY, 2009, 112 (01) : 257 - 264
  • [44] Development and feasibility of an exercise therapy intervention for older women with advanced epithelial ovarian cancer referred to neoadjuvant chemotherapy prior to possible interval debulking surgery
    Jespersen, Eva
    Cobian, Cristina Daviu
    Jorgensen, Trine L.
    Minet, Lisbeth R.
    Schnack, Tine H.
    Vinther, Anders
    GYNECOLOGIC ONCOLOGY REPORTS, 2024, 54
  • [45] The role of minimally invasive interval debulking surgery in advanced epithelial ovarian cancer
    Menderes, Gulden
    Black, Jonathan D.
    Azodi, Masoud
    EXPERT REVIEW OF ANTICANCER THERAPY, 2016, 16 (09) : 899 - 901
  • [46] Minimal residual disease at primary debulking surgery versus complete tumor resection at interval debulking surgery in advanced epithelial ovarian cancer: A survival analysis
    Ghirardi, V
    Moruzzi, M. C.
    Bizzarri, N.
    Vargiu, V.
    D'Indinosante, M.
    Garganese, G.
    Pasciuto, T.
    Loverro, M.
    Scambia, G.
    Fagotti, A.
    GYNECOLOGIC ONCOLOGY, 2020, 157 (01) : 209 - 213
  • [47] Neoadjuvant Chemotherapy plus Interval Cytoreductive Surgery with or without Hyperthermic Intraperitoneal Chemotherapy (NIHIPEC) in the Treatment of Advanced Ovarian Cancer: A Multicentric Propensity Score Study
    Llueca, Antoni
    Ibanez, Maria Victoria
    Cascales, Pedro
    Gil-Moreno, Antonio
    Bebia, Vicente
    Ponce, Jordi
    Fernandez, Sergi
    Arjona-Sanchez, Alvaro
    Muruzabal, Juan Carlos
    Veiga, Nadia
    Diaz-Feijoo, Berta
    Celada, Cristina
    Gilabert-Estelles, Juan
    Aghababyan, Cristina
    Calero, Alicia
    Lacueva, Javier
    Segura, Juan Jose
    Maiocchi, Karina
    Llorca, Sara
    Villarin, Alvaro
    Climent, Maria Teresa
    Delgado, Katty
    Serra, Anna
    Gomez-Quiles, Luis
    Llueca, Maria
    CANCERS, 2023, 15 (17)
  • [48] AN ASSESSMENT OF OVARIAN CANCER FEMALE PATIENTS' DEATH AND SURVIVAL RATE AFTER SURGICAL INTERVENTION: NEOADJUVANT CHEMOTHERAPY VERSUS PRIMARY DEBULKING SURGERY
    Fatima, Sidra
    Zulfiqar, Mehwish
    Yousaf, Muhammad Usman
    INDO AMERICAN JOURNAL OF PHARMACEUTICAL SCIENCES, 2019, 6 (03): : 4960 - 4966
  • [49] Radical Surgical Procedures in Advanced Ovarian Cancer and Differences Between Primary and Interval Debulking Surgery
    Mitsopoulos, Vasilis
    Innamaa, Anni
    Lippiatt, Jonathan
    Plevris, Nikolaos
    Biliatis, Ioannis
    ANTICANCER RESEARCH, 2020, 40 (10) : 5869 - 5875
  • [50] Serum Albumin as a Predictor of Survival after Interval Debulking Surgery for Advanced Ovarian Cancer (AOC): A Retrospective Study
    Dai, Dairui
    Balega, Janos
    Sundar, Sudha
    Kehoe, Sean
    Elattar, Ahmed
    Phillips, Andrew
    Singh, Kavita
    JOURNAL OF INVESTIGATIVE SURGERY, 2022, 35 (02) : 426 - 431